Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | CASP7 | P55210 | 1/20 | 0.51 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7419391 | 1.00 | ALDH1A1 (0.62) | ALDH1A1MEN1KMT2AL3MBTL1MAPT | |
| SCHEMBL24202473 | 1.00 | ALDH1A1 (0.62) | ALDH1A1MEN1KMT2AL3MBTL1MAPT | |
| SCHEMBL31722182 | 1.00 | ALDH1A1 (0.62) | ALDH1A1MEN1KMT2AL3MBTL1MAPT | |
| Hydrochloric Acid SCHEMBL10520152 | 0.98 | ALDH1A1 (0.60) | ALDH1A1MEN1KMT2AL3MBTL1MAPT | |
| SCHEMBL1653800 | 0.86 | ALDH1A1 (0.54) | ALDH1A1MEN1KMT2AL3MBTL1MAPT | |
| SCHEMBL10974753 | 0.86 | ALDH1A1 (0.54) | ALDH1A1MEN1KMT2AL3MBTL1MAPT | |
| SCHEMBL24202568 | 0.84 | ALDH1A1 (0.57) | ALDH1A1MEN1KMT2AL3MBTL1MAPT | |
| SCHEMBL11197769 | 0.84 | ALDH1A1 (0.62) | ALDH1A1MEN1KMT2AL3MBTL1MAPT | |
| SCHEMBL24202566 | 0.84 | ALDH1A1 (0.57) | ALDH1A1MEN1KMT2AL3MBTL1MAPT | |
| SCHEMBL28465359 | 0.84 | ALDH1A1 (0.54) | ALDH1A1MEN1KMT2AL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100297680-A1 | METHODS FOR ASSESSING THE RISK FOR DEVELOPMENT OF CARDIOVASCULAR DISEASE | UNIVERSITY OF WASHINGTON (US) | 2010-11-25 | — | — | US | claimed |
| US-20080261250-A1 | Methods for Assessing the Risk for Development of Cardiovascular Disease | UNIVERSITY OF WASHINGTON (US) | 2008-10-23 | — | — | US | claimed |
| EP-1787116-A4 | METHODS FOR ASSESSING THE RISK FOR DEVELOPMENT OF CARDIOVASCULAR DISEASE | UNIV WASHINGTON (US) | 2008-05-28 | — | — | EP | claimed |
| EP-1787116-A1 | METHODS FOR ASSESSING THE RISK FOR DEVELOPMENT OF CARDIOVASCULAR DISEASE | University of Washington (US) | 2007-05-23 | — | — | EP | claimed |
| WO-2006014628-A1 | METHODS FOR ASSESSING THE RISK FOR DEVELOPMENT OF CARDIOVASCULAR DISEASE | UNIVERSITY OF WASHINGTON (US) | 2006-02-09 | — | — | WO | claimed |
| CN-113774084-B | Overexpression of N-glycosylation pathway-modulating genes to modulate glycosylation of recombinant proteins | 美国安进公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-110662558-B | Treatment or amelioration of metabolic disorders using GLP-1 receptor agonists coupled to Gastric Inhibitory Peptide Receptor (GIPR) antagonists | 美国安进公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20240101625-A1 | EPHA2 T-CELL EPITOPE AGONISTS AND USES THEREFORE | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-03-28 | — | — | US | disclosed |
| US-11787846-B2 | EphA2 T-cell epitope agonists and uses therefore | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2023-10-17 | — | — | US | disclosed |
| EP-4199968-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | Ambrx, Inc. (US) | 2023-06-28 | — | — | EP | disclosed |
| CN-116113634-A | Modulus modifier and film thereof | 齐默尔根公司 | 2023-05-12 | — | — | CN | disclosed |
| US-20220145339-A1 | METHOD FOR PREPARATION OF PRIMARY AMINE COMPOUNDS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2022-05-12 | — | — | US | disclosed |
| US-5500414-A | TREATMENT OF PERIODONTAL DISESASE, INHIBITION OF ZINC METALLOPROTEASES | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1996-03-19 | — | — | US | disclosed |
| WO-1995015335-A2 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1995-06-08 | — | — | WO | disclosed |
| US-5389612-A | Treating infections caused by clostridium histolyticum and pseudomonas aeruginosa; enzyme inhibitors | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1995-02-14 | — | — | US | disclosed |
| EP-0315959-B1 | Quinoxaline compounds and their preparation and use | NOVO NORDISK AS (DK) | 1994-03-02 | — | — | EP | disclosed |
| EP-0565450-A1 | Use of peptide derivatives for the manufacture of medicaments inhibiting endopeptidases 24.15 and 24.16 | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1993-10-13 | — | — | EP | disclosed |
| US-5026704-A | Neuroleptic agent, quisqualate-antagonist | NOVO NORDISK A/S (DK) | 1991-06-25 | — | — | US | disclosed |
| US-4948794-A | NEUROLEPTIC AGENTS | A/S FERROSAN (DK) | 1990-08-14 | — | — | US | disclosed |
| EP-0315959-A2 | Quinoxaline compounds and their preparation and use | NOVO NORDISK A/S (DK) | 1989-05-17 | — | — | EP | disclosed |